New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 10, 2014
14:23 EDTSIGA, PIPPharmAthene awarded lump sum expectation damages from SIGA Technologies
PharmAthene (PIP) announced that on August 8, the Delaware Court of Chancery issued a Memorandum Opinion and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA Technologies (SIGA) smallpox antiviral, Tecovirimat. In addition, the Court ordered SIGA to pay prejudgment interest and varying percentages of PharmAthene's reasonable attorneys' and expert witness fees."We are extremely pleased by the Chancery Court's ruling to award PharmAthene lump sum expectancy damages that it suffered due to SIGA's breach of contract," said Eric I. Richman, President and CEO. "We look forward to working with our damages expert to calculate the lump sum damage amounts in accordance with the Court's decision and its instructions in the accompanying order."
News For PIP;SIGA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
10:16 EDTPIPPharmAthene reports Valortim IDIQ contract fulfilled
PharmAthene announced that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity, or IDIQ, contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority for the company's anthrax anti-toxin, Valortim. Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use